Souhaitez-vous accéder aux communiqués récents ?

ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...

Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a...

ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments...

Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites ...

Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening...

ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...

Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...

Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...